Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Cash (2016 - 2025)

China Pharma Holdings' Change in Cash history spans 16 years, with the latest figure at $77487.0 for Q4 2025.

  • For Q4 2025, Change in Cash rose 184.4% year-over-year to $77487.0; the TTM value through Dec 2025 reached -$281767.0, up 64.64%, while the annual FY2025 figure was -$281767.0, 64.64% up from the prior year.
  • Change in Cash reached $77487.0 in Q4 2025 per CPHI's latest filing, up from -$357407.0 in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $4.4 million in Q4 2021 to a low of -$1.5 million in Q2 2022.
  • Average Change in Cash over 5 years is -$30627.1, with a median of -$129104.0 recorded in 2022.
  • Peak YoY movement for Change in Cash: surged 620.12% in 2021, then crashed 1631.12% in 2025.
  • A 5-year view of Change in Cash shows it stood at $4.4 million in 2021, then tumbled by 101.28% to -$56327.0 in 2022, then skyrocketed by 195.81% to $53967.0 in 2023, then tumbled by 270.13% to -$91812.0 in 2024, then soared by 184.4% to $77487.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Change in Cash are $77487.0 (Q4 2025), -$357407.0 (Q3 2025), and $212344.0 (Q2 2025).